A Phase 3 interventional study of aprepitant and Comparator: Placebo to aprepitant in Chemotherapy-induced Nausea and Vomiting (CINV), sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing aprepitant in Vomiting — 3 open to participants now, 3 under way, 1 of them phase 3. Aprepitant · Vomiting.
Among the 61 studies testing aprepitant in Vomiting, this one is the 6th largest by enrollment, is one of 6 that started in 2009, is one of 15 in phase 3, and was the 21st registered.
794 studies on the registry are indexed under Vomiting; 99 are open to participants now.
Browse Vomiting studies →3 of the 61 studies testing aprepitant in Vomiting are open now, in 2 countries. Recruiting first, the newest first:
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–75
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 57 Vomiting studies recruiting now, 27 (47%) set no upper age limit and 24 (42%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 421 is above the median of 103 across 674 interventional studies indexed under Vomiting.
Median enrollment 92 across the 61 interventional studies. Of the 45 that completed or were terminated, 25 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 61 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
29 studies in Vomiting by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 29 finished, 20 (69%) have results posted.
Among the 29 studies in Vomiting by Merck & Co., Inc, this one is the 12th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2009, is one of 10 in phase 3, and was the 16th registered.
Merck & Co., Inc’s Vomiting studies by the year they started, since 2002.
1 of the studies testing aprepitant in Vomiting that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371728Sir Mortimer B. Davis - Jewish General HospitalEffect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 61 studies testing aprepitant in Vomiting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 29 in Vomiting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cycle 1:
Cycle 2 (optional):
appropriate by the investigator and will not pose unwarranted risk to the patient.
study procedures.
dose is still no less than 70 mg/m\^2.
Exclusion Criteria:
Cycles 1 \& 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: aprepitant · Drug: granisetron · Drug: dexamethasone
Drug: Comparator: Placebo to aprepitant · Drug: dexamethasone · Drug: granisetron
Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg
Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg
Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg
Day 1: IV granisetron 3 mg prior to administration of cisplatin
Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1
Overall phase was defined as 0 to 120 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.
Time frame: 0 to 120 hours
Proportion of Participants With Complete Response in the Acute Phase of Cycle 1
Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.
Time frame: 0 to 24 hours
Proportion of Participants With Complete Response in the Delayed Phase of Cycle 1
Delayed phase was defined as 25 to 120 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.
Time frame: 25 to 120 hours
Proportion of Participants With No Vomiting in the Overall Phase of Cycle 1
Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy. No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).
Time frame: 0 to 120 hours
Proportion of Participants With No Vomiting in the Acute Phase of Cycle 1
Acute Phase was defined as 0 to 24 hours following initiation of chemotherapy.
Time frame: 0 to 24 hours
Proportion of Participants With No Vomiting in the Delayed Phase of Cycle 1
Delayed Phase was defined as 25 to 120 hours following initiation of chemotherapy
Time frame: 25 to 120 hours
Proportion of Participants With No Impact on Daily Life in Cycle 1
The Functional Living Index-Emesis is a self-administered, validated emesis \& nausea-specific questionnaire. Participants completed the questionnaire 5 days post chemotherapy. It had 9 questions each on nausea and vomiting. "No impact of chemotherapy-induced nausea \& vomiting (CINV) on daily life" was defined as an average item score of \>6 on the 7-point scale (i.e., \>108 total score). The scale was in the opposite direction for questions 3, 6, 11, 15 \& 18. For each question: score ranged from 1 (worst) to 7 (best, i.e., no CINV). Total score range was 7 (worst) to 126 (best).
Time frame: 0 to 120 hours
Time to First Vomiting Episode in Cycle 1
Time from administration of chemotherapy to first vomiting episode.
Time frame: 0 to 120 hours
| Milestone | Aprepitant (MK-0869) | Placebo |
|---|---|---|
| Started | 209 | 212 |
| Completed | 189 | 199 |
| Not completed | 20 | 13 |
| Withdrew: Adverse event | 4 | 1 |
| Withdrew: Withdrawal by subject | 3 | 8 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Lost to follow-up | 11 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Milestone | Aprepitant (MK-0869) | Placebo |
|---|---|---|
| Started | 110 | 130 |
| Completed | 101 | 118 |
| Not completed | 9 | 12 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 6 | 9 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Progressive disease | 0 | 1 |
Overall phase was defined as 0 to 120 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.
| Proportion of participants | Aprepitant (MK-0869) | Placebo |
|---|---|---|
| Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1 | 0.696 | 0.570 |
Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.
| Proportion of participants | Aprepitant (MK-0869) | Placebo |
|---|---|---|
| Proportion of Participants With Complete Response in the Acute Phase of Cycle 1 | 0.794 | 0.793 |
Delayed phase was defined as 25 to 120 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.
| Proportion of participants | Aprepitant (MK-0869) | Placebo |
|---|---|---|
| Proportion of Participants With Complete Response in the Delayed Phase of Cycle 1 | 0.740 | 0.594 |
Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy. No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).
| Proportion of participants | Aprepitant (MK-0869) | Placebo |
|---|---|---|
| Proportion of Participants With No Vomiting in the Overall Phase of Cycle 1 | 0.706 | 0.570 |
Acute Phase was defined as 0 to 24 hours following initiation of chemotherapy.
| Proportion of participants | Aprepitant (MK-0869) | Placebo |
|---|---|---|
| Proportion of Participants With No Vomiting in the Acute Phase of Cycle 1 | 0.804 | 0.798 |
Delayed Phase was defined as 25 to 120 hours following initiation of chemotherapy
| Proportion of participants | Aprepitant (MK-0869) | Placebo |
|---|---|---|
| Proportion of Participants With No Vomiting in the Delayed Phase of Cycle 1 | 0.740 | 0.594 |
The Functional Living Index-Emesis is a self-administered, validated emesis \& nausea-specific questionnaire. Participants completed the questionnaire 5 days post chemotherapy. It had 9 questions each on nausea and vomiting. "No impact of chemotherapy-induced nausea \& vomiting (CINV) on daily life" was defined as an average item score of \>6 on the 7-point scale (i.e., \>108 total score). The scale was in the opposite direction for questions 3, 6, 11, 15 \& 18. For each question: score ranged from 1 (worst) to 7 (best, i.e., no CINV). Total score range was 7 (worst) to 126 (best).
| Proportion of participants | Aprepitant (MK-0869) | Placebo |
|---|---|---|
| Proportion of Participants With No Impact on Daily Life in Cycle 1 | 0.705 | 0.683 |
Time from administration of chemotherapy to first vomiting episode.
| Hours | Aprepitant (MK-0869) | Placebo |
|---|---|---|
| Time to First Vomiting Episode in Cycle 1 | 77.0 ± 2.5 | 76.0 ± 2.8 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aprepitant (MK-0869), Cycle 1 & Cycle 2 | — | 5/205 (2.4%) | 123/205 (60%) |
| Placebo, Cycle 1 & Cycle 2 | — | 2/210 (1%) | 124/210 (59%) |
| Event | Aprepitant (MK-0869), Cycle 1 & Cycle 2 | Placebo, Cycle 1 & Cycle 2 |
|---|---|---|
| DeathGeneral disorders | 1/205 | 0/210 |
| Lung infectionInfections and infestations | 1/205 | 0/210 |
| Neutrophil count decreasedInvestigations | 1/205 | 1/210 |
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/205 | 0/210 |
| Cerebral infarctionNervous system disorders | 1/205 | 0/210 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/205 | 1/210 |
| InfectionInfections and infestations | 0/205 | 1/210 |
| White blood cell count decreasedInvestigations | 0/205 | 1/210 |
| Event | Aprepitant (MK-0869), Cycle 1 & Cycle 2 | Placebo, Cycle 1 & Cycle 2 |
|---|---|---|
| White blood cell count decreasedInvestigations | 50/205 | 49/210 |
| Neutrophil count decreasedInvestigations | 33/205 | 39/210 |
| ConstipationGastrointestinal disorders | 38/205 | 31/210 |
| Decreased appetiteMetabolism and nutrition disorders | 30/205 | 29/210 |
| VomitingGastrointestinal disorders | 7/205 | 29/210 |
| NauseaGastrointestinal disorders | 12/205 | 21/210 |
| Alanine aminotransferase increasedInvestigations | 20/205 | 21/210 |
| Haemoglobin decreasedInvestigations | 15/205 | 11/210 |
| DiarrhoeaGastrointestinal disorders | 13/205 | 8/210 |
| FatigueGeneral disorders | 13/205 | 4/210 |
| Age, Continuous(years) | Aprepitant (MK-0869) | Placebo | Total |
|---|---|---|---|
| Mean | 53.1 ± 10.1 | 53.6 ± 10.6 | 53.4 ± 10.3 |
| Sex: Female, Male(Participants) | Aprepitant (MK-0869) | Placebo | Total |
|---|---|---|---|
| Female | 71 | 73 | 144 |
| Male | 138 | 139 | 277 |
| Region of Enrollment(participants) | Aprepitant (MK-0869) | Placebo | Total |
|---|---|---|---|
| China | 209 | 212 | 421 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Aug 2009 to primary completion in Apr 2010, 7 months.
Results were first posted in Sep 2011, 1 year 5 months after primary completion. A results delay was requested in Apr 2011.
Of 56 phase 3 interventional studies under Vomiting, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aprepitant